Intraductal endoscopic radiofrequency ablation for the treatment of hilar non-resectable malignant bile duct obstruction
Open Access
- 1 January 2014
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Endoscopy
- Vol. 6 (1), 13-19
- https://doi.org/10.4253/wjge.v6.i1.13
Abstract
AIM: To evaluate the safety and technical success of endoscopic radiofrequency ablation (RFA) for palliative treatment of malignant hilar bile duct obstruction. METHODS: In this study, a recently CE and FDA-approved endoscopic RFA catheter was first tested in an ex vivo pig liver model to study the effect of electrosurgical variables on the extent of the area of induced necrosis. Subsequently, a retrospective analysis was conducted of all patients treated with endoscopic RFA for malignant biliary obstruction at our center between February 2012 and April 2013. All patients received an additional plastic stent implantation into the biliary tree following RFA. RESULTS: In the pig model, ablation time of 60-90 seconds using the bipolar soft coagulation mode at 8-10 watts with an effect of 8 was found to be the most feasible setting. Twelve patients (5 females, 7 males; mean age, 70 years) underwent 19 endoscopic RFA (range, 1-5) sessions. Deployment of RFA was successful in all patients. Systemic chemotherapy was administered in four patients. We observed biliary bleeding 4-6 wk after the intervention in three cases and two of these patients died: in one patient, spontaneous hemobilia occurred, whereas bleeding started during stent extraction in the other. In the third patient, bleeding was stopped by insertion of a non-covered self-expanding metal stent. Another three patients developed cholangitis during follow-up. Seven patients died during follow-up and median survival was 6.4 mo (95%CI: 0.05-12.7) from the time of the first RFA. CONCLUSION: Endoscopic RFA is an easy to perform and technically highly successful procedure. However, hemobilia possibly associated with RFA occurred in three of our patients. Therefore, larger prospective studies are needed to further evaluate the safety and efficacy of this promising new method.Keywords
This publication has 16 references indexed in Scilit:
- Cholangiocarcinoma—controversies and challengesNature Reviews Gastroenterology & Hepatology, 2011
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerThe New England Journal of Medicine, 2010
- Unresectable Cholangiocarcinoma: Comparison of Survival in Biliary Stenting Alone Versus Stenting With Photodynamic TherapyClinical Gastroenterology and Hepatology, 2008
- Biliary tract cancers: From pathogenesis to endoscopic treatmentBest Practice & Research Clinical Gastroenterology, 2007
- Factors Associated With Increased Survival After Photodynamic Therapy for CholangiocarcinomaClinical Gastroenterology and Hepatology, 2007
- Survival Difference in Patients with Photodynamic Therapy of Nonresectable Bile Duct Cancer Using Different HematoporphyrinsGastrointestinal Endoscopy, 2007
- Surgical and Palliative Management and Outcome in 184 Patients With Hilar CholangiocarcinomaAnnals of Surgery, 2006
- Palliation of Nonresectable Bile Duct Cancer: Improved Survival After Photodynamic TherapyThe American Journal of Gastroenterology, 2005
- Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective studyGastroenterology, 2003
- CholangiocarcinomaAnnals of Surgery, 1996